Moderna | 8-K: Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates
May 2 18:33
Moderna | DEFA14A: Others
Mar 21 20:51
Moderna | DEF 14A: Definitive information statements
Mar 21 20:51
Moderna | PRE 14A: Preliminary proxy statements relating to merger or acquisition
Mar 12 04:10
Moderna | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Feb 24 05:28
Moderna | 8-K: Moderna Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Updates
Feb 22 19:36
Moderna | 8-K: Updates of Progress on the Pipeline of Transformative mRNA Medicines and Preliminary Financial Results
Jan 8 13:00
Moderna | 8-K: Moderna announces that Arpa Garay Will Leave His Position
Dec 12, 2023 21:04
Moderna | 8-K: Chief Commercial Officer Arpa Garay Cancelled the Garay 10b5-1 Plan on November 6, 2023
Nov 6, 2023 21:02
Moderna | 8-K: Moderna Reports Third Quarter 2023 Financial Results
Nov 2, 2023 18:33
Moderna | 8-K: Moderna Statement on Anticipated 2023 COVID-19 Sales
Oct 16, 2023 20:59
Moderna | 8-K: Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
Sep 11, 2023 20:08
Moderna | 8-K: Moderna Reports Second Quarter 2023 Financial Results
Aug 3, 2023 18:33
Moderna | 8-K: Notice of the 2023 Annual Meeting of Stockholders
May 6, 2023 04:05
Moderna | S-3ASR: Automatic shelf registration statement of securities of well-known seasoned issuers
May 5, 2023 19:31
Moderna | 8-K: Moderna Reports First Quarter 2023 Financial Results
May 4, 2023 18:33
Moderna | DEFA14A: Others
Apr 14, 2023 22:58
Moderna | DEFA14A: Others
Mar 16, 2023 04:17
Moderna | DEF 14A: Definitive proxy statements
Mar 16, 2023 04:16
Moderna | 8-K: Moderna Reports Fourth Quarter and Fiscal Year 2022 Financial Results
Feb 23, 2023 20:03
No Data
No Data